Glenmark Pharmaceuticals Ltd - Stock Valuation and Financial Performance

BSE: 532296 | NSE: GLENMARK | Pharmaceuticals & Drugs | Small Cap

Glenmark Pharma Share Price

1,047.40 4.70 0.45%
as on 12-Apr'24 10:20

DeciZen - make an informed investing decision on Glenmark Pharma

Overall Rating
Bole Toh

1. Quality

2. Valuation


3. Price Trend

Glenmark Pharmaceuticals stock performance -

mw4me loader
P/E Ratio (CD):
Market Cap:
29,673.5 Cr.
52-wk low:
52-wk high:

Is Glenmark Pharmaceuticals Ltd an attractive stock to invest in?

1. Is Glenmark Pharmaceuticals Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Glenmark Pharmaceuticals Ltd is a average quality company.

2. Is Glenmark Pharmaceuticals Ltd undervalued or overvalued?

The key valuation ratios of Glenmark Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Glenmark Pharmaceuticals Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Glenmark Pharmaceuticals Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

10 Year X-Ray of Glenmark Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Glenmark Pharmaceuticals Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

ROCE % 11.5%8%13.3%16.4%10.1%9.2%8.8%10.9%10.3%2.7%-
Value Creation

Growth Parameters

Growth Parameters Colour Code Guide

Sales 5,9456,6817,5629,0799,0749,86510,64110,94412,30512,99012,258
Sales YoY Gr.-12.4%13.2%20.1%-0.1%8.7%7.9%2.9%12.4%5.6%-
Adj EPS 20.212.626.74326.824.223.335.137.84.1-25.2
YoY Gr.--38%113%60.7%-37.6%-9.7%-3.8%50.8%7.7%-89.1%-
BVPS (₹) 11065.7128.6159.2182.6198.3214.7249.6321.5335.1314.6
Adj Net
Cash Flow from Ops. 8544823456571,6481,3241,3921,1311,109625-
Debt/CF from Ops. 3.87.911.


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 9.1%7.4%6.9%5.6%
Adj EPS -16.2%-31.2%-43.8%-89.1%
Share Price 6.2% 10% 27% 113.6%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on
Equity %
Op. Profit
Mgn %
Net Profit
Mgn %
Debt to
Working Cap
Cash Conv.

Recent Performance Summary

Debt to equity has declined versus last 3 years average to 0.46

Return on Equity is Poor

Sales growth has been subdued in last 3 years 6.88%

Sales growth is not so good in last 4 quarters at 5.10%

Latest Financials - Glenmark Pharmaceuticals Ltd.

Standalone Consolidated
TTM EPS (₹) 14.8 -25.2
TTM Sales (₹ Cr.) 7,448 12,258
BVPS (₹.) 650.6 314.6
Reserves (₹ Cr.) 18,329 8,850
P/BV 1.62 3.34
PE 71.31 0.00
From the Market
52 Week Low / High (₹) 481.05 / 1059.15
All Time Low / High (₹) 1.89 / 1261.95
Market Cap (₹ Cr.) 29,674
Equity (₹ Cr.) 28.2
Face Value (₹) 1
Industry PE 48

Management X-Ray of Glenmark Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Glenmark Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
Operating Expenses 4,8545,4676,1257,0437,4598,2808,9438,8609,98510,712
Manufacturing Costs430927624674786890843803985998
Material Costs1,7861,5382,2472,5522,9633,2843,6243,6204,3124,454
Employee Cost 1,0261,2131,3781,6411,8722,0562,2552,3442,4472,781
Other Costs 1,6121,7881,8762,1761,8382,0492,2212,0922,2402,479
Operating Profit 1,0911,2141,4372,0371,6151,5861,6982,0842,3202,278
Operating Profit Margin (%) 18.3%18.2%19.0%22.4%17.8%16.1%16.0%19.0%18.9%17.5%
Other Income 11720379120816050167317
Interest 189190179237286335377353298350
Depreciation 217300234264302326417444487611
Exceptional Items 0-1870-8101673345-261-766
Profit Before Tax 6975441,0441,4911,1191,3011,0961,3821,441868
Tax 151334301383315376320412448491
Profit After Tax 5462097431,109804925776970994377
PAT Margin (%) 9.2%3.1%9.8%12.2%8.9%9.4%7.3%8.9%8.1%2.9%
Adjusted EPS (₹)20.07.726.339.328.532.827.534.433.410.5
Dividend Payout Ratio (%)10%26%8%5%7%6%9%7%7%24%

Balance Sheet

(All Figures are in Crores.)

Equity and Liabilities

Shareholders Fund 2,9831,7833,6284,4915,1535,5956,0577,0439,0709,456
Share Capital 27272828282828282828
Reserves 2,9561,7563,6004,4635,1255,5666,0297,0159,0429,428
Minority Interest13-0-0-0-0-0-0-0351365
Long Term Debt2,4292,5742,4874,5364,1423,5744,0433,8892,5723,852
Short Term Debt353348787187295303443513370350
Trade Payables1,3631,9481,9411,7431,8702,2212,1262,2382,2892,392
Others Liabilities 7711,656285-505-1842145613877451,150
Total Liabilities 7,9128,3099,12810,45311,27511,90613,22914,06915,39717,566

Fixed Assets

Gross Block3,6333,4954,3014,7705,3686,5278,2708,73210,21311,296
Accumulated Depreciation7431,4801,7072,0152,3382,8573,2413,6034,3265,094
Net Fixed Assets2,8902,0152,5942,7553,0303,6705,0295,1295,8876,202
CWIP 2064775437081,1221,3991,2221,3821,0101,251
Investments 0171716153025255045
Trade Receivables2,1562,5122,4932,4042,3322,1952,4092,5723,1014,099
Cash Equivalents 8017768571,0581,2359381,1111,1391,4121,470
Others Assets9271,2431,0571,3731,5121,4231,2981,5461,4381,521
Total Assets 7,9128,3099,12810,45311,27511,90613,22914,06915,39717,566

Cash Flow

(All Figures are in Crores.)
Cash Flow From Operating Activity 8544823456571,6481,3241,3921,1311,109625
PBT 6975441,0441,4911,1191,3011,0961,3821,441868
Adjustment 7105233917275713306366457871,472
Changes in Working Capital -290-267-612-862309136127-386-561-1074
Tax Paid -263-318-478-699-352-443-467-510-558-641
Cash Flow From Investing Activity -368-540-880-712-1,013-699-784-675-333-528
Capex -373-538-889-733-1,023-610-775-675-358-551
Net Investments 00000-1550-10-1
Others 5-28219-74-1303523
Cash Flow From Financing Activity -98199699543-468-739-445-442-520-77
Net Proceeds from Shares 1329350000000
Net Proceeds from Borrowing 260478-4411,400-290-381-116-67-889650
Interest Paid -194-179-180-184-213-270-301-294-251-312
Dividend Paid -63-54-68-68-68-68-69-70-93-137
Others -113-47452-606102-2041-11712-279
Net Cash Flow 388141163488166-1141641425519
ROE (%)18.998.7927.4627.3116.6717.2113.3214.8112.334.07
ROCE (%)15.0412.418.5320.5414.7716.4714.0415.314.199.17
Asset Turnover Ratio0.830.830.880.940.840.850.851.851.891.8
PAT to CFO Conversion(x)1.562.310.460.592.051.431.791.171.121.66
Working Capital Days
Receivable Days11512611997958479363744
Inventory Days54596874847975323134
Payable Days186354310263222227219220192192

Glenmark Pharmaceuticals Ltd Stock News

Glenmark Pharmaceuticals Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Glenmark Pharma on 12-Apr-2024 10:20 is ₹1,047.4.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 12-Apr-2024 10:20 the market cap of Glenmark Pharma stood at ₹29,673.5.
The latest P/E ratio of Glenmark Pharma as of 12-Apr-2024 10:20 is 71.31.
The latest P/B ratio of Glenmark Pharma as of 12-Apr-2024 10:20 is 1.62.
The 52-week high of Glenmark Pharma is ₹1,059.2 and the 52-week low is ₹481.1.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Glenmark Pharma is ₹7,448 ( Cr.) .

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd. (GPL) was incorporated in 1977. It was founded with a vision to emerge as a leading integrated research-based, global pharmaceutical company. Its branded generics business has a significant presence in markets across emerging economies including India. It is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in many countries. Glenmark’s key therapy focus areas globally are respiratory, dermatology and oncology. Its API business sells products in many countries including the US, various countries in the EU, South America and India.

India is the largest market in terms of revenue for the organization. The formulations business has five manufacturing facilities; three in India and two overseas. These facilities are approved by several regulatory bodies. The facility at Baddi, Himachal Pradesh, India is also approved by MHRA and USFDA for semi-solids. The overseas facilities are situated in Brazil and the Czech Republic. While the manufacturing facility in Brazil services requirements of the Latin American region, the Czech facility services requirements of the Central Eastern Europe region. Glenmark has also invested in a dedicated R&D facility for formulations development. This R&D centre, situated near Nashik, India is engaged in developing specialty/ branded formulations for global markets.

Business area of the company

The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Specialty Business: Drug Discovery: Glenmark’s ground-breaking drug discovery effort is primarily focused in the areas of inflammation [asthma/COPD, rheumatoid arthritis etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain]. Specialty Business: Formulations Business: Glenmark’s formulations business is currently organized many regions - India, Latin America, Central Eastern Europe and Semi Regulated Markets of Africa/Asia/CIS. The formulations business focuses on therapeutic areas viz. dermatology, anti-infective, respiratory, cardiac, diabetes, gynecology, CNS, and oncology.


  • It was conferred with the Pharmaexcil Gold Award for New Chemical Entities 2015.
  • SCRIP crowned Glenmark as the ‘Best Pharma Company in Emerging markets’ and ‘Best Overall Pipline’ at SCRIP Awards 2011 in London. 
  • Swiss Ambassador's award for Exceptional Innovation - 2012.
  • It received the Bombay Chamber of Commerce and Industry Civic Award 2014. 
  • It was conferred with the prestigious Golden Peacock Management Award - 2015 for its Environment Sustainability initiatives at the Goa manufacturing facility.



  • Glenmark Pharmaceuticals has entered into a settlement and license agreement with Sepracor Inc to market generic Eszopiclone tablets.


  • Forest Laboratories and Glenmark Sign Development Agreement for Worldwide Collaboration on Novel Agents to treat Chronic Inflammatory Conditions.


  • Glenmark entered into an out-licensing deal with Forest Labs for its novel molecule targeting mPGES-1 Inhibitor.


  • Glenmark announced the Strategic Development & Licensing Agreement with Celon, Poland for generic Seretide Accuhaler in Europe. In the same year, Glenmark received approval for generic Seretide in Russia.


  • Glenmark launched ezetimibe, the first and only generic version of Zetia in the United States for the treatment of high cholesterol.


  • Glenmark Pharmaceuticals and Mankind Pharmaceuticals have inked a sub-licensing agreement to co-market sodium glucose co-transporter-2 (SGLT2) inhibitor, Remogliflozin Etabonate (Remogliflozin) in India.
  • Glenmark Pharmaceuticals’ partner -- Seqirus Pty (Seqirus) has received marketing approval for Ryaltris from the Therapeutic Goods Administration (TGA), Australia.


  • Glenmark Pharmaceuticals has launched NINDANIB (Nintedanib 100 and 150 mg capsules) for the treatment of pulmonary fibrosis in India.
  • Glenmark Pharmaceuticals has launched the world’s first hypertension awareness symbol, in collaboration with Association of Physicians of India (API) and Hypertension Society of India (HSI). 
  • Glenmark Pharmaceuticals has launched of a Single Inhaler Triple Therapy AIRZ-FF.
  • Glenmark Pharmaceuticals has entered into an agreement with Hindustan Unilever (HUL) for divestment of its VWash brand and other extensions.
  • Glenmark Pharmaceuticals’ Swiss subsidiary, Glenmark Specialty S.A., has entered into an exclusive licensing agreement with Hikma Pharmaceuticals PLC (Hikma) for commercializing its novel nasal spray Ryaltris in the US.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.